Generic entry timeline

Dovonex generics — when can they launch?

Dovonex (CALCIPOTRIENE) · · 2 active US patents · 0 expired

Earliest patent expiry
2026-05-26
expired
Full patent estate to
2028-05-07
complete protection through 2028
FDA approval
1993

Where Dovonex sits in the generic timeline

All listed Orange Book patents for Dovonex have expired. Generic entry is permitted, and ANDA filers can launch without patent infringement risk. Hatch-Waxman exclusivity (NCE/ODE/PED) may still apply if recently approved.

Under US Hatch-Waxman, a generic enters via an ANDA (Abbreviated New Drug Application) and may file with one of four Paragraph IV certifications attacking the brand's listed patents. If the brand sues within 45 days, a 30-month FDA approval stay is triggered. First Para IV filer typically gets 180-day market exclusivity.

Patent estate by type — active patents

Method-of-use patents only carve out specific indications; generics can launch with a "skinny label" omitting those uses. Composition-of-matter patents block the molecule itself.

  • Method of Use — 2 patents

FDA U-codes carved out by Dovonex patents

Method-of-use patents are listed against specific FDA Patent Use Codes ("U-codes") representing carved-out indications. Generics can launch with a label that omits these uses.

U-codeDescription
U-1280(no description)

Sample patent estate

Showing 2 of 2 active US patents. View full estate on the Dovonex drug page →

  • US8629128 Method of Use · expires 2026-05-26
    This patent protects a pharmaceutical composition, specifically a vitamin formulation, in the form of an aerosol foam or oil-in-water emulsion.
    USPTO title: Vitamin formulation
  • US8263580 Method of Use · expires 2028-05-07
    This patent protects a pharmaceutical composition, specifically a vitamin formulation, in the form of an aerosol foam or oil-in-water emulsion.
    USPTO title: Vitamin formulation

Sources

Patent term extensions (PTR, pediatric exclusivity), Hatch-Waxman 30-month stays, and FDA regulatory exclusivity (NCE/ODE/PED) may shift the effective generic entry date. Not legal advice.

Get generic entry alerts

Free Pharma CI alerts on Dovonex — get notified the moment an ANDA Paragraph IV certification is filed, a 30-month stay is triggered, or a generic launches. First 2 drugs free.

Subscribe free →